Please enable JavaScript.
Coggle requires JavaScript to display documents.
DNA Vaccines :pencil2: - Coggle Diagram
DNA Vaccines
:pencil2:
DNA Vaccines in clinical trials
Advantage
Cost effective
Well tolerated by patients
hamped
Produce anti DNA antibodies
Disrupt cellular processes
Low a lever of immunogenicity
DNA vaccines in humans bodies
Builds long-lasting immunity
Prompt helper T cells and B cells to multiply
B cells to multiply and crate memory cells and activate cytotoxic
Goals
Creating a strong cellular response
Building a potent humoral
Much safer than a live-virus vaccine
DNA vaccine plasmids are not living
Thus nonreplicating
No risk that they may cause an illness
Change in the near future is in clinical trials
Valuation
2013 : Near $244 milion
2019 : Grow to $2.7 milion
Improve the vaccines by
Nanotechnologies
New biotechnologies
DNA vaccines is a different
approach
DNA vaccines use genetic material to elicit an immune response from
The virus
The bacteria
Process
Isolate a gene from the target pathogen
Spilice the gene into double vector ( bactecrial plasmid )
The plasmid can be replicated and purifled
The vaccine is ready to be injected
Create vaccine that are safer
First began to test only in 1990s
Most are still in the process of research and clinical trials
The global market for research and development for the vaccine has grown tremendously over the past several years